News

Hemarina raises €6.3m in Series B
Enlarge image

BusinessFrance

Hemarina raises €6.3m in Series B

12.07.2012 - The French marine biotechnology specialist Hemarina SA has raised €6.3m to bring its first organ transplant product to market.

The company, founded in March 2007, is centred on the research and development of marine oxygen carriers for therapeutic and industrial applications. It develops extracellular haemoglobin for four core business programmes: organ transplantation and tissue conservation; blood oxygen carriers; infections and wound healing; and bio-production. The Morlaix based company is predicting to bring its first medical application product by end of 2013 in the field of kidney transplantation.

„This new round of investment shows the trust of our new partners and board members“, stated Franck Zal, CEO of Hemarina. The syndicate was led by Inserm Transfert Initiative and includes historical investors such as Finistère Angels, Armor Angels, XMP and Arkéa Capital Investissement; and also a new entrant which is a family office represented and mandated by M. Maurice Lesaffre.

Since last November, Hemarina receives research funding from the French National Research Agency (ANR) to push forward its lead candidate Hemo2Life solution for preserving kidney grafts. In a public private partnership, Hemarina will attempt to validate its oxygen carrier or the storage of kidney transplants in preservation solutions and machine perfusion systems. To do so, the French marine biotech specialist has teamed up with the INSERM U927 research unit “Ischemia-reperfusion in kidney transplantation” at the Poitiers University Hospital, and the Health, Life, and Agricultural Sciences Infrastructures (IBiSA) facility ‘Surgery, Experimentation, Transplantation’ in Surgères.

http://www.european-biotechnology-news.com/news/news/2012-03/hemarina-raises-eur63m-in-series-b.html

AntibodiesDenmarkNetherlands

22.05.2015 Dutch arGEN-X and Danish LEO Pharma are pairing up to develop antibody-based treatments for the chronic inflammation that causes many skin conditions.

M&ANetherlandsGermanyEU

12.05.2015 US pharma is coming to European biotech to fill their pipeline. Pfizer is paying €77.5m for an option on Dutch AM-Pharma, while Juno Therapeutics acquired German biotech Stage Cell Therapeutics for around €72m.

Rare diseasesItalyGermanyPoland

15.05.2015 Rome-based pharmaceutical group Sigma-Tau has sold its blood cancer drug programme Oncaspar to US company Baxter, who aims to spin out its biopharma business.



BiologicsFinlandNetherlandsEU

26.05.2015 The Finnish Medicines Agency Fimea has joined the Dutch MEB in its stance on the interchangeability of biosimilars. The Fimea now sees physician-driven switching of biologics as unproblematic.

SurveyGermany

06.05.2015 More revenue, more staff, more funding: in the German biotech industry, all signs are pointing towards growth.

M&AUKSweden

18.05.2015 Double deal for allergy: UK’s speciality biopharma Circassia is boosting its asthma pipeline with the acquisition of Swedish asthma specialist Aerocrine as well as fellow British Prosonix.

BusinessSwedenFrance

02.06.2015 After disappointing Phase III results for immunotherapy tasquinimod and the subsequent discontinuation of the prostrate cancer drug, Swedish Active Biotech is now severely downsizing its operations.

FinancingUK

20.05.2015 The Scottish Government has announced it will double the amount of funds for rare diseases. The New Medicines Fund that was created last year for this purpose will be increased to £80m (€112m).

EPOSwitzerland

30.05.2015 Pharma giant Roche has out-licensed its anaemia drug Mircera to fellow Swiss healthcare company Galenica.

Events

All Events

Partner-Events

Frankfurt am Main (DE)

ACHEMA 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NEUROVIVE PHARMACEUTICAL AB (S)26.20 SEK19.09%
  • PROTHENA PLC (IE)42.69 USD6.86%
  • GW PHARMACEUTICALS (UK)657.00 GBP5.65%

FLOP

  • ANTISOMA (UK)1.00 GBP-35.48%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • ACTIVE BIOTECH (S)9.45 SEK-10.85%

TOP

  • CHRONTECH PHARMA (S)0.02 SEK100.0%
  • GALAPAGOS (B)51.79 EUR37.8%
  • FLAMEL TECHNOLOGIES (F)19.55 USD36.3%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)26.20 SEK-48.4%
  • CYTOS (CH)0.59 CHF-41.6%
  • ANTISOMA (UK)1.00 GBP-35.5%

TOP

  • CELLECTIS (F)38.88 EUR518.1%
  • WILEX (D)4.11 EUR470.8%
  • ADOCIA (F)67.61 EUR440.4%

FLOP

  • CHRONTECH PHARMA (S)0.02 SEK-81.8%
  • ACTIVE BIOTECH (S)9.45 SEK-72.0%
  • THROMBOGENICS (B)5.33 EUR-70.0%

No liability assumed, Date: 02.06.2015